RT Journal Article SR Electronic T1 Biodistribution and Radiation Dosimetry for a Probe Targeting Prostate-Specific Membrane Antigen for Imaging and Therapy JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 855 OP 861 DO 10.2967/jnumed.115.156133 VO 56 IS 6 A1 Ken Herrmann A1 Christina Bluemel A1 Martina Weineisen A1 Margret Schottelius A1 Hans-Jürgen Wester A1 Johannes Czernin A1 Uta Eberlein A1 Seval Beykan A1 Constantin Lapa A1 Hubertus Riedmiller A1 Markus Krebs A1 Saskia Kropf A1 Andreas Schirbel A1 Andreas K. Buck A1 Michael Lassmann YR 2015 UL http://jnm.snmjournals.org/content/56/6/855.abstract AB Prostate-specific membrane antigen (PSMA) is a promising target for diagnosis and treatment of prostate cancer. EuK-Subkff-68Ga-DOTAGA (68Ga-PSMA Imaging & Therapy [PSMA I&T]) is a recently introduced PET tracer for imaging PSMA expression in vivo. Whole-body distribution and radiation dosimetry of this new probe were evaluated. Methods: Five patients with a history of prostate cancer were injected intravenously with 91–148 MBq of 68Ga-PSMA I&T (mean ± SD, 128 ± 23 MBq). After an initial series of rapid whole-body scans, 3 static whole-body scans were acquired at 1, 2, and 4 h after tracer injection. Time-dependent changes of the injected activity per organ were determined. Mean organ-absorbed doses and effective doses were calculated using OLINDA/EXM. Results: Injection of 150 MBq of 68Ga-PSMA I&T resulted in an effective dose of 3.0 mSv. The kidneys were the critical organ (33 mGy), followed by the urinary bladder wall and spleen (10 mGy each), salivary glands (9 mGy each), and liver (7 mGy). Conclusion: 68Ga-PSMA I&T exhibits a favorable dosimetry, delivering organ doses that are comparable to (kidneys) or lower than those delivered by 18F-FDG.